Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03358329
Other study ID # P500-0717
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 13, 2017
Est. completion date January 17, 2019

Study information

Verified date November 2019
Source Intersect ENT
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ENCORE Study is designed to evaluate the repeat administration of the S8 Sinus Implant in chronic sinusitis (CS) patients with recurrent nasal polyps.


Description:

The ENCORE Study is a prospective open-label, non-randomized, multicenter study in CS patients who had undergone prior endoscopic sinus surgery (ESS) including bilateral total ethmoidectomy and present with bilateral ethmoid polyposis.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 17, 2019
Est. primary completion date January 17, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient has provided written informed consent using a form approved by the reviewing institutional review board (IRB) and sponsor.

2. Patient is = 18 years of age.

3. Patient is willing and able to comply with protocol requirements.

4. Patient has a confirmed diagnosis of CS with nasal polyps, as defined in the 2016 "International Consensus Statement on Allergy and Rhinology".

5. Patient has undergone prior ESS including bilateral total ethmoidectomy at least 90 days prior to screening.

6. Patient has evidence of bilateral ethmoid sinus obstruction due to polyposis warranting intervention (polyp grade = 2 on each side).

7. Patient is able to tolerate daily use of Mometasone Furoate Nasal Spray (MFNS).

8. Patient is able to tolerate topical/local anesthesia.

9. In the opinion of the investigator, patient's ethmoid sinus anatomy is amenable to in-office bilateral placement of the S8 Sinus Implant (i.e., able to pass into the middle meatus on both sides the S8 Sinus Implant with 20 mm in nominal length and 7 mm in compressed diameter).

10. Female patients of reproductive potential must not be pregnant or nursing and must agree to not become pregnant during their participation in the study.

11. Female patients of childbearing potential must agree to use consistent and acceptable method(s) of birth control during their participation in the study.

Exclusion Criteria:

1. Patient has extensive ethmoid sinus polyp grade (grade 4 on at least one side).

2. Patient has extensive adhesions/synechiae (grade 3 or 4).

3. Patient has used parenteral and injected steroids (e.g., Kenalog injection) during 30 days prior to the baseline procedure.

4. Patient has used oral steroids, budesonide or other sinus steroid irrigations/rinses, nebulized steroids administered nasally or budesonide drops during 14 days prior to the baseline procedure.

5. Patient has oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or asthma.

6. Patient has known history of allergy or intolerance to corticosteroids or mometasone furoate.

7. Patient has used monoclonal antibodies for asthma, allergies or nasal polyps (e.g., Dupixent, Nucala, Xolair) during 30 days prior to the baseline procedure.

8. Patient requires monoclonal antibodies for asthma, allergies or nasal polyps during the duration of the study.

9. Patient has presence of physical obstruction that would preclude access and placement of the S8 Sinus Implant in the middle meatus (e.g., severe septal deviation, septal spur, very small middle meatus, total obstruction of the sinonasal passage with severe adhesion, scarring, polypoid edema or polyps).

10. Patient has known history of human immunodeficiency virus (HIV) or immunoglobulin G or A subclass deficiency.

11. Patient has clinical evidence of acute sinusitis (AS), as defined in the 2016 "International Consensus Statement on Allergy and Rhinology".

12. Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on prior computed tomography (CT) scan, necrotic sinus tissue).

13. Patient has evidence of severe concomitant disease or condition expected to compromise survival or ability to complete assessments during the 365-day study follow-up period (e.g., cancer).

14. Patient is currently participating in another clinical study.

15. Patient has previously undergone ESS and experienced a cerebrospinal fluid (CSF) leak or has residual compromised vision as a result of a complication in a prior ESS procedure.

16. Patient has known dehiscence of the lamina papyracea.

17. Patient has evidence of active tuberculosis or active viral illness (e.g., ocular herpes simplex, chickenpox, measles).

18. Patient has known history or diagnosis of glaucoma or ocular hypertension (prior ocular exam with intraocular pressure of >21 mmHg and pressure lowering medication given) or posterior subcapsular cataract.

Study Design


Intervention

Combination Product:
S8 Sinus Implant
In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses

Locations

Country Name City State
United States BreatheAmerica of Albuquerque Albuquerque New Mexico
United States Charlotte Eye, Ear, Nose and Throat Associates Concord North Carolina
United States Associated Surgical Specialists Covington Louisiana
United States Advanced ENT & Allergy Louisville Kentucky
United States DuPage Medical Group Naperville Illinois
United States Yale University School of Medicine New Haven Connecticut
United States Madison ENT New York New York
United States Bridgerland Clinical Research North Logan Utah
United States Sacramento ENT Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
Intersect ENT

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Implant-Related Serious Adverse Events Evaluated via tabulation of implant-related serious adverse events (SAE) reported by subjects between consent and Day 365. 365 days
Secondary SNOT-22 Total Score Sino-Nasal Outcomes Test (SNOT-22) is a validated disease-specific symptom-scoring instrument consisting of 22 questions, each scored on a 6-point scale of 0 (no problem) to 5 (probably as bad as it can be) based on the subject's recollection of symptoms over the past 2 weeks. The total score ranges from 0 to 110, with a higher score reflecting greater symptom burden. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value from baseline. Negative values for change from baseline indicate reduction (improvement) in sino-nasal symptoms. Baseline, 90 days, 180 days
Secondary Nasal Obstruction/Congestion Score Determined on a scale of 0 (no symptoms) to 3 (severe symptoms) based on the subject's recollection of symptoms over the past week using a reflective paper questionnaire. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value at baseline. Negative values for change from baseline to follow-up indicate reduction (improvement) in nasal obstruction/congestion. Baseline, 90 days, 180 days
See also
  Status Clinical Trial Phase
Completed NCT02266810 - Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus Phase 3
Completed NCT01706484 - Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis Phase 3
Completed NCT01197612 - Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis Phase 3
Completed NCT04163978 - Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS) Phase 2
Completed NCT04418622 - Evolution of the Endonasal Microbiota in Patients With Chronic Rhinosinusitis
Not yet recruiting NCT06070311 - Wound Healing After Endoscopic Sinus Surgery N/A
Not yet recruiting NCT05454163 - Post-radiotherapy Rhinosinusitis in Children
Withdrawn NCT01185808 - Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps N/A
Completed NCT01700725 - Gulf War Illness Nasal Irrigation Study Phase 2
Withdrawn NCT00671281 - The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery N/A
Completed NCT00447837 - Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis Phase 2
Recruiting NCT04362501 - Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Phase 2
Completed NCT05035654 - LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study) Phase 2
Completed NCT02562924 - The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery N/A
Completed NCT01007799 - Vitamin D for Chronic Sinusitis N/A
Withdrawn NCT02981017 - Improvement of Outcomes in Draf III/Endoscopic Modified Lothrop Procedure N/A
Completed NCT04041609 - LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study) Phase 2
Recruiting NCT01854619 - Photodynamic Therapy for the Treatment of Chronic Rhinosinusitis N/A
Completed NCT00924404 - Xylitol Versus Saline in Chronic Sinusitis N/A
Not yet recruiting NCT03903432 - The Feasibility of Using MRI During ESS N/A